Tricyclic inhibitors of poly(ADP-ribose) polymerases

Details Tricyclic inhibitors of poly(ADP-ribose) polymerases Tricyclic inhibitors of poly(ADP-ribose) polymerases

2005-12-20

2005-12-20

Kifle, Bruck (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Unsubstituted hydrocarbyl chain between the ring and the -c-...

C546S084000

Reexamination Certificate

active

06977298

ABSTRACT:
Compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease.As cancer therapeutics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.

REFERENCES:
patent: 3642820 (1972-02-01), Hester et al.
patent: 3883590 (1975-05-01), Schmerling
patent: 3900477 (1975-08-01), Philipp et al.
patent: 3932406 (1976-01-01), Buttner et al.
patent: 3950343 (1976-04-01), Philipp et al.
patent: 3978066 (1976-08-01), Philipp et al.
patent: 4033960 (1977-07-01), Seng et al.
patent: 4910193 (1990-03-01), Buchheit
patent: 5215738 (1993-06-01), Lee et al.
patent: 5246933 (1993-09-01), Turnbull et al.
patent: 5272143 (1993-12-01), Benson et al.
patent: 5342946 (1994-08-01), Hamilton
patent: 5587384 (1996-12-01), Zhang et al.
patent: 5589483 (1996-12-01), West
patent: 5659082 (1997-08-01), Flitter et al.
patent: 5756510 (1998-05-01), Griffin et al.
patent: 5756548 (1998-05-01), Flitter et al.
patent: 0018493 (1980-11-01), None
patent: 0 525 584 (1992-07-01), None
patent: 2297089 (1996-07-01), None
patent: 57144286 (1982-09-01), None
patent: 6434988 (1989-02-01), None
patent: WO 9509159 (1995-04-01), None
patent: WO 9524379 (1995-09-01), None
patent: WO 9526186 (1995-10-01), None
patent: WO 9704771 (1997-02-01), None
patent: WO 9719934 (1997-06-01), None
patent: WO 9732576 (1997-09-01), None
patent: WO 9833802 (1998-08-01), None
patent: WO 9851307 (1998-11-01), None
patent: WO 9851308 (1998-11-01), None
patent: WO 9911622 (1999-03-01), None
patent: WO 9911623 (1999-03-01), None
patent: WO 9911624 (1999-03-01), None
patent: WO 9911628 (1999-03-01), None
patent: WO 9911644 (1999-03-01), None
patent: WO 9911645 (1999-03-01), None
patent: WO 99/11649 (1999-03-01), None
patent: WO 9959973 (1999-11-01), None
patent: WO 9959975 (1999-11-01), None
patent: WO 99/59975 (1999-11-01), None
patent: WO 97/04771 (2000-02-01), None
patent: WO 01/23386 (2001-04-01), None
patent: WO 01/23390 (2001-04-01), None
Muchowski, et al., Isocarbostyrils. II. Conversion of 2-methyl-4-acyl-5-nitroisocarbostyrils to 2-substituted indole-4-carboxylic acids, Chemical Abstracts, vol. 75, No. 23, p. 304, 1971.
C.V. Ananthanarayanan, et al., 3,4-Bridged indoles: Part II. Synthesis of 6-keto-1,5-dihydro-45-diazepino '6, 5, 4-cd!indoles and 3,4-disunstituted indoles as 5-HT antagonist, Chemical Abstracts, vol. 88, No. 17, p. 543, 1978.
M. Somei, et al., Azepinoindole derivatives as ergoline alkaloid-type pharmaceuticals, Chemical Abstracts, vol. 111, No. 11, p. 743, 1989.
R.E. Bowman, et al., 1,3,4,5-tetrahydrobenz 'cd!indoles and related compounds. Part II, Journal of the Chemical Society, Perkin transactions 1., pp. 1926-32, 1972.
Homing et al., “Isocarbostyrils. II. Conversion of 2-Methyl-4-acyl-5-nitroisocarbostyrils to 2-Substituted indole-4-carboxylic acids,”Canadian Journal of Chemistry,49 (17), 2797-2802 (1971).
Clark et al., “1,9-Alkano-Bridged 2,3,4,5-Tetrahydro-1H-3-benzazepines with Affinity for the α2-Adrenoceptor and the 5-HT1AReceptor,”J. Med. Chem.,33, 633-641 (1990).
Santangelo et al., “A Convenient Synthesis of 9-Hydroxy-3,4,5,6-Tetrahydro-1H-Azepino [5,4,3-cd] Indole from 7-Methoxyindole,”Synthetic Communications,23(19), 2717-2725 (1993).
Gmeiner et al., “Synthesis and Dopamine Receptor Binding of 3-Phenylazepino [5,4,3-c,d] indole Derivatives,”Arch. Pharm.,328, 329-332 (1995).
Zhang, “PARP Inhibition Results in Substantial Neuroprotection in Cerebral Ischemia,”Cambridge Healthtech Institute's New Therapeutic Opportunities,Sep. 23-24, Alexis Park Resort, Las Vegas, Nevada (1998).
Saldeen et al., “Nicotinamide-induced apoptosis in insulin producing cells is associated with cleavage of poly (ADP-ribose) polymerase,”Molecular and Cellular Endocrinology,139, 99-107 (1998).
Tentori et al., “Role of Wild-Type p53 on the Antineoplastic Activity of Temozolomide Alone or Combined with Inhibitors of Poly(ADP-Ribose) Polyerase,”The Journal of Pharmacology and Experimetal Therapeutics,285(2), 884-893 (1998).
Endres et al., “Protective effects of 5-iodo-6-amino-1,2-benzopyrone, an inhibitor of poly(ADP-ribose) synthetase against peroxynitrite-induced glial damage and stroke development,”European Journal of Pharmacology,351, 377-382 (1998).
Pennisi, “A Possible New Partner for Telomerase,”Science,282, 1395, 1397 (1998).
Szabo et al., “Protective effect of an inhibitor of poly (ADP-ribose) synthetase in collagen-induced arthritis,”Portland Press Proc.,15 (Biology of Nitric Oxide, Part 6), 280 (1998).
Geneste et al., “Recherches en serie de l'imidazo- (4,5,1-jk)-benzodiazepine-1,4 et de l'imidazo- (1,5,4-ef)—benzodiazepine—1,5,”Eur. J. Med. Chem.,13(1), 53-59 (1978); with English abstract.
Endres et al., “Ischemic Brain Injury Is Mediated by the Activation of Poly(ADP-Ribose) Polymerase,”Journal of Cerebral Blood Flow and Metabolism,17, 1143-1151 (1997).
Suto et al., “Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors of poly (ADP-ribose) polyermase,”Anti Cancer Drug Design,7, 107-117 (1991).
Banasik et al., “Specific Inhibitors of Poly (ADP-Ribose0 Synthetase and Mono (ADP-Ribosyl) transferase,”The Journal of Biological Chemistry,267(3), 1569-1575 (1992).
Hester, Jr. et al., “Pyrrolo [3,2,1-jk][1,4] benzodiazepines and Pyrrolo [1,2,3-ef][1,5] benzodiazepines Which Have Central Nervous System Activity”,Journal of Medicinal Chemistry,13(5), 827-835 (1970).
Smith et al., “Tankyrase, a Poly(ADP-Ribose) Polymerase at Human Telomeres,”Science,282, 1484-1487 (1998).
Griffin et al., “Resistance-Modifying Agents. 5. Synthesis and Biological Properties of Quinazololinone Inhibitors of the DNA Repair Enzyme Poly(ADP-ribose) Polymerase (PARP),”Journal of Medicinal Chemistry,5247-5256 (1998).
Bowman et al., “Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064,”British Journal of Cancer,78(10), 1269-1277 (1998).
Denny et al., “Potential Antitumor Agents. 59. Structure-Activity Relationships for 2-Phenylbenzimidazole-4-carboxamides, a New Class of ‘Minimal’ DNA-Intercalating Agents Which May Not Act via Topoisomerase II,”Journal of Medicinal Chemistry,33, 814-819 (1990).
Gilchrist et al., “Cyclisation ofortho-SubstitutedN-Arylbenzimidoyl Nitrenes,”J.C.S. Perkin I,2303-2307 (1978).
Kubo et al., “Nonpeptide Angiotensin II Receptor Antagonists. Synthesis and Biological Activity of Benzimidazoles,”J. Med. Chem.,36, 1772-1784 (1993).
Schneller et al., “Synthesis ofproximal-Benzoguanine and a Simplified Synthesis ofproximal-Benzohypoxanthine,”J. Org. Chem.,51, 4067-4070 (1986).
Choi, “At the Scene of Ishemic Brain Injury: Is PARP a Perp?,”Nature Medicine,3(10), 1073-1074 (1997).
Sculley et al., “The determination of kinetic constants governing the slow, tight-binding inhibition of enzyme-catalysed reactions,”Biochimica et Biophysica Acta,874, 44-53 (1986).
Pullen et al., “Chiral separation retention mechanisms in high-performance liquid chromatography using bare silica stationary phase and β-cyclodextrin as a mobile phase additive,”Journal of Chromatography A,691, 187-193 (1995).
Pullen et al., “Direct Determination of Substituted Azepinoindole Enantiomers in Rat Plasma Using Silica Stationary Phase and β-Cyclodextrin as a Mobile Phase Additive,”Analytical Chemistry,67, 1903-1906 (1995).
Griffin et al., “Novel potent inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP),”Anti-Cancer Drug Design,10, 507-514 (1995).
Naidong et al., “Stereospecific determinations of (±)-DU-124884 and its metabolites (

Affiliated with

Also associated with

Rating

Tricyclic inhibitors of poly(ADP-ribose) polymerases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tricyclic inhibitors of poly(ADP-ribose) polymerases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tricyclic inhibitors of poly(ADP-ribose) polymerases will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3508332